Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Non-Current Deferred Tax Liability (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Non-Current Deferred Tax Liability for 16 consecutive years, with $733000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deferred Tax Liability rose 3.68% to $733000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $733000.0, a 3.68% increase, with the full-year FY2024 number at $710000.0, down 8.51% from a year prior.
  • Non-Current Deferred Tax Liability was $733000.0 for Q3 2025 at Harvard Bioscience, roughly flat from $734000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $2.4 million in Q2 2022 to a low of $546000.0 in Q1 2023.
  • A 5-year average of $1.0 million and a median of $764000.0 in 2024 define the central range for Non-Current Deferred Tax Liability.
  • Peak YoY movement for Non-Current Deferred Tax Liability: skyrocketed 54.39% in 2022, then tumbled 72.52% in 2023.
  • Harvard Bioscience's Non-Current Deferred Tax Liability stood at $1.6 million in 2021, then tumbled by 62.13% to $590000.0 in 2022, then surged by 31.53% to $776000.0 in 2023, then decreased by 8.51% to $710000.0 in 2024, then increased by 3.24% to $733000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Non-Current Deferred Tax Liability are $733000.0 (Q3 2025), $734000.0 (Q2 2025), and $717000.0 (Q1 2025).